Full Text Journal Articles by
Author Sejin Chung

Advertisement

Find full text journal articles








Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer.

Erik S Knudsen, Vishnu Kumarasamy, Sejin Chung, Amanda Ruiz, Paris Vail, Stephanie Tzetzo, Jin Wu, Ram Nambiar, Jared Sivinski, Shailender S Chauhan, Mukund Seshadri, Scott I Abrams, Jianmin Wang, Agnieszka K Witkiewicz,

OBJECTIVE:This study exploits the intersection between molecular-targeted therapies and immune-checkpoint inhibition to define new means to treat pancreatic cancer. DESIGN:Patient-derived cell lines and xenograft models were used to define the response to CDK4/6 and MEK inhibition in the tumour compartment. Impacts relative to immunotherapy were performed using subcutaneous and orthotopic ... Read more >>

Gut (Gut)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Targeting dual signaling pathways in concert with immune checkpoints for the treatment of pancreatic cancer

Erik Knudsen, Vishnu Kumarasamy, Sejin Chung, Paris Vail, Stephanie Tzetzo, Amanda Ruiz, Mukund Seshadri, Scott Abrams, Jianmin Wang, Agnieszka Witkiewicz,

ABSTRACT Pancreatic cancer harbors a poor prognosis due to the lack of effective systemic therapies. Here we interrogated means to target key effector pathways down-stream from KRAS. We found that combination treatment with MEK and CDK4/6 inhibitors was effective across a broad range of PDX models in delaying tumor progression. ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer.

Sejin Chung, Paris Vail, Agnieszka K Witkiewicz, Erik S Knudsen,

PURPOSE:Cancer cells often have deficiencies in cell-cycle control mechanisms and could be dependent on specific cell-cycle checkpoints to maintain viability. Because of the documented role of KRAS in driving replication stress, we targeted the checkpoint governing DNA replication using CHK1 kinase inhibitors in pancreatic ductal adenocarcinoma (PDAC) models and examined ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2019, 25(7):2290-2304]

Cited: 6 times

View full text PDF listing >>



Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer.

Erik S Knudsen, Vishnu Kumarasamy, Amanda Ruiz, Jared Sivinski, Sejin Chung, Adam Grant, Paris Vail, Shailender S Chauhan, Tun Jie, Taylor S Riall, Agnieszka K Witkiewicz,

Pancreatic ductal adenocarcinoma (PDAC), like many KRAS-driven tumors, preferentially loses CDKN2A that encodes an endogenous CDK4/6 inhibitor to bypass the RB-mediated cell cycle suppression. Analysis of a panel of patient-derived cell lines and matched xenografts indicated that many pancreatic cancers have intrinsic resistance to CDK4/6 inhibition that is not due ... Read more >>

Oncogene (Oncogene)
[2019, 38(18):3355-3370]

Cited: 5 times

View full text PDF listing >>



Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer.

Agnieszka K Witkiewicz, Sejin Chung, Rachel Brough, Paris Vail, Jorge Franco, Christopher J Lord, Erik S Knudsen,

Approximately 30% of triple-negative breast cancers (TNBCs) exhibit functional loss of the RB tumor suppressor, suggesting a target for precision intervention. Here, we use drug screens to identify agents specifically antagonized by the retinoblastoma tumor suppressor (RB) using CDK4/6 inhibitors. A number of candidate RB-synthetic lethal small molecules were identified, ... Read more >>

Cell Rep (Cell reports)
[2018, 22(5):1185-1199]

Cited: 11 times

View full text PDF listing >>





Advertisement

Disclaimer
0.6333 s